Intravascular large B-cell lymphoma (IVLBCL): A clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5 Blood 109: 478-485

Author(s): Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, et al.


Intravascular large B-cell lymphoma (IVLBCL) is pathologically distinct with a broad clinical spectrum and immunophenotypic heterogeneity. A series of 96 patients with IVLBCL (median age, 67 years; range, 41-85 years; 50 men) was reviewed. Anemia/thrombocytopenia (84%), hepatosplenomegaly (77%), B symptoms (76%), bone marrow involvement (75%), and hemophagocytosis (61%) were frequently observed. The International Prognostic Index score was high or high-intermediate in 92%. For 62 patients receiving anthracycline-based chemotherapies, median survival was 13 months. CD5, CD10, Bcl-6, MUM1, and Bcl-2 were positive in 38%, 13%, 26%, 95%, and 91% of tumors, respectively. All 59 CD10− IVLBCL cases examined were nongerminal center B-cell type because they lacked the Bcl-6+MUM1− immunophenotype. CD5 positivity was associated with a higher prevalence of marrow/blood involvement and thrombocytopenia and a lower frequency of neurologic abnormalities among patients with CD10−IVLBCL. Compared with 97 cases of de novo CD5+CD10−diffuse LBCL, 31 cases of CD5+CD10−IVLBCL exhibited higher frequencies of poor prognostic parameters, except age. Multivariate analysis in IVLBCL revealed that a lack of anthracycline-based chemotherapies (P < .001, hazard ratio [HR]: 9.256), age older than 60 years (P = .012, HR: 2.459), and thrombocytopenia less than 100 × 109/L (P = .012, HR: 2.427) were independently unfavorable prognostic factors; CD5 positivity was not. Beyond immunophenotypic diversity, IVLBCL constitutes a unique group with aggressive behavior.

Similar Articles

Non-Hodgkin lymphoma

Author(s): Shankland KR, Armitage JO, Hancock BW

Treatment of malignant lymphoma

Author(s): Berthold D, Ghielmini M

Lymphomas of the female genital tract: A study of 186 cases and review of the literature

Author(s): Kosari F, Daneshbod Y, Parwaresch R, Krams M, Wacker HH

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Author(s): Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, et al.

Intravascular lymphoma: The oncologist's "great imitator"

Author(s): Zuckerman D, Seliem R, Hochberg E

Intravascular large B-cell lymphoma of the uterus: A case with favorable clinical outcome

Author(s): Yamamoto T, Morita K, Iriyama N, Wakui K, Hiroi A, et al.

Primary intravascular large B cell lymphoma of the endometrium

Author(s): Xia Y, Wang Y, Jiang Y, Yu W, Li Y, et al.

Conservative management in primary genital lymphomas: The role of chemotherapy

Author(s): Signorelli M, Maneo A, Cammarota S, Isimbaldi G, Garcia Parra R, et al.

Malignant lymphoma

Author(s): Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, et al.

Sonographic findings of uterine cervical lymphoma manifesting as multinodular lesions

Author(s): Park SB, Lee YH, Song MJ, Cho HC, Lee MS, et al.

Primary gynecologic lymphoma: Imaging findings

Author(s): Onyiuke I, Kirby AB, McCarthy S